Nuclear cap-binding protein subunit 2-like (NCBP2L)

Nuclear cap-binding protein subunit 2-like (NCBP2L) is a protein-coding gene predicted to enable RNA cap binding activity and to participate in mRNA splicing via the spliceosome[5]. NCBP2L is a member of the nuclear cap-binding protein complex family, closely related to NCBP2, which binds the 5′ cap structure of mRNA in the nucleus and supports mRNA processing and gene expression in eukaryotic cells[1][3][5]. Its exact biological role is not fully characterized, but it is likely to function in RNA metabolism, similar to its paralog NCBP2, including participation in RNA cap binding and nuclear mRNA processing complexes[5]. There is no evidence that NCBP2L is an established therapeutic target, nor are interacting drugs, mechanisms of action, biomarkers, or specific safety considerations documented for this gene/protein[5]. It has been reported as associated with Seckel syndrome, but not as a canonical causative target[5].

Other names

dJ820B18.1NCBP2Lnuclear cap-binding protein subunit 2-like